GLENMARK

Pharmaceuticals

Glenmark Pharmaceuticals ltd

NSE: GLENMARKBSE: 532296ISIN: INE935A01035
₹2,192.00
-13.10 · -0.59%
As of 24 Jul 2026
Open
₹2,182.00
High
₹2,248.80
Low
₹2,182.00
Prev Close
₹2,205.10
52W High
₹2,474.00
52W Low
₹1,792.60
Volume
4.30 L
Mkt Cap
₹61,901 Cr
Fundamentals
Valuation & profitability
Market Cap
₹61,901 Cr
P/E Ratio
0
EPS (TTM)
₹42.84
Book Value
₹278.00
Dividend Yield
0.18%
ROCE
12.4%
ROE
32.3%
Sales Growth
3%
Face Value
₹1.00
Company overview
Glenmark Pharmaceuticals ltd

Glenmark Pharmaceuticals Limited or GLENMARK

Glenmark Pharmaceuticals was being incorporated in 1977, and then it entered into the dermatology market by 1979 via the launch of its Candid Cream. Soon it became a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with the help of eight molecules in various stages of the clinical development. It also operates in the formulation business in over 95 countries, which also includes India. It has a significant presence in branded generics markets across emerging economies, including India. And its subsidiary, named Glenmark Generics Limited has a fast growing and robust US generics business. It also markets APIs to regulated & semi-regulated countries and employs nearly 6000 people in over 80 countries worldwide. It has approximately twelve manufacturing facilities in over four countries and also has five R&D centers.

The Glenmark was also chosen as one of the "Best Pharma Company in the World – SME" and "Best Company across emerging markets" for 2008 by SCRIP, it is also the most significant selling as well as the most respected pharmaceutical magazine in the world. And then Forbes, which is another leading international publication, recognized Glenmark as the "Best under a Billion Dollar companies in Asia" for 2008.

The vision of this company is to emerge as a leading integrated research-based, global pharmaceutical company and over the decades, it has established itself as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) as well as NBEs (New Biological Entity). Now, they have several molecules in various stages of the preclinical and clinical development, and it is also primarily focused in the areas of Oncology, Respiratory & Dermatology.

The generics business services the requirements of the developed markets like US & Western Europe and API business sells its products in approximately 80 countries worldwide which includes the US, and various other countries in the EU, and South America and India.

And with the 17 manufacturing facilities and 5 R&D centers which are dedicated to the goal of enriching lives across the world and they believe that the real force behind their continued successes is the dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world.'

Key highlights
Auto-generated from live data
  • Trades at a P/E of 0, with a return on equity (ROE) of 32.3%.
  • GLENMARK is trading above 1 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bearish technical setup.
  • Year-to-date it is up 9.65%, and up 21.83% over the past year.
  • At ₹2,192.00 it sits about 59% of the way up its 52-week range (₹1,792.60–₹2,474.00).
  • Offers a dividend yield of 0.18%.
  • Market capitalisation stands at ₹61,901 Cr.
Price chart
Daily candles + volume · SMA 20 / 50 / 200 · stored OHLC
Shareholding pattern

Shareholding data syncs daily.

Performance
Stock returns vs Nifty 50
10D
-3.83%
Nifty -0.64%
20D
-0.50%
Nifty -1.72%
50D
+2.73%
Nifty +2.68%
100D
+0.00%
Nifty -1.14%
200D
+8.55%
Nifty -8.93%
YTD
+9.65%
Nifty -8.59%
52W
+21.83%
Nifty -7.86%
Moving averages
Simple moving averages vs current price
1/5 above · Bearish
SMA 10-Day
₹2,250.48Below
SMA 20-Day
₹2,238.71Below
SMA 50-Day
₹2,236.90Below
SMA 100-Day
₹2,226.36Below
SMA 200-Day
₹2,088.48Above
Price ranges
Where the price sits in each window
10-Day range₹2,192.00
₹2,166.00₹2,326.10
20-Day range₹2,192.00
₹2,142.80₹2,326.10
50-Day range₹2,192.00
₹2,101.00₹2,427.00
200-Day range₹2,192.00
₹1,792.60₹2,474.00
YTD range₹2,192.00
₹1,842.00₹2,474.00
52-Week range₹2,192.00
₹1,792.60₹2,474.00
Technical signals
Unfilled gaps acting as support / resistance
Unfilled Gap Up On 13 Feb, 2023 : 404.30 ~ 403.40SUPPORT
Unfilled Gap Up On 13 Apr, 2020 : 253.00 ~ 250.75SUPPORT
Annual financials
Revenue, profit & EPS by financial year
YearRevenueNet ProfitEPSNPM
Mar 2023₹8,221 Cr₹1,209 Cr₹42.8414.71%
Mar 2022₹8,142 Cr₹1,998 Cr₹70.8024.54%
Mar 2021₹10,944 Cr₹970 Cr₹34.388.86%
Mar 2021₹10,944 Cr₹970 Cr₹34.388.86%
Mar 2020₹10,641 Cr₹776 Cr₹27.507.29%
Mar 2020₹10,641 Cr₹776 Cr₹27.507.29%
Mar 2019₹9,865 Cr₹925 Cr₹32.789.38%
Mar 2019₹9,865 Cr₹925 Cr₹32.789.38%
Mar 2018₹9,074 Cr₹804 Cr₹28.498.86%
Mar 2017₹9,079 Cr₹1,109 Cr₹39.2912.22%
Mar 2016₹7,562 Cr₹743 Cr₹26.339.83%
Mar 2015₹6,563 Cr₹210 Cr₹7.313.2%
Peer comparison
Other companies in Pharmaceuticals
CompanyP/EBook ValueSales Growth
SUNPHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD.
39.1₹98.3310.1%
MARKSANS
MARKSANS PHARMA LTD.
23.8₹11.855.8%
MOREPENLAB
MOREPEN LABORATORIES LTD.
20.81₹6.4316.6%
NEULANDLAB
NEULAND LABORATORIES LTD.
23.48₹542.169.35%
GUFICBIO
Gufic BioSciences Ltd.
24.16₹10.8520.41%
DIVISLAB
DIVI'S LABORATORIES LTD.
41.01₹266.779.47%
DRREDDY
DR.REDDY'S LABORATORIES LTD.
19.73₹852.691.07%
RPGLIFE
RPG LIFE SCIENCES LTD.
17.14₹105.025.73%
GLAND
Gland Pharma Ltd
53.6₹242.00
ZYDUSLIFE
Zydus Lifesciences Ltd
8.23₹166.005%
SMSPHARMA
SMS PHARMACEUTICALS LTD.
9.58₹42.07-8.73%
CIPLA
CIPLA LTD.
15.36₹209.710.7%
Dividend history
Per share, by ex-date
Ex-Date: 12 Sept 2022₹2.50
Ex-Date: 08 Sept 2021₹2.50
Ex-Date: 17 Sept 2020₹2.50
Ex-Date: 19 Sept 2019₹2.00
Ex-Date: 25 Jul 2019₹1.25
Ex-Date: 19 Sept 2018₹2.00
Ex-Date: 14 Aug 2018₹1.00
Ex-Date: 20 Sept 2017₹2.00
Ex-Date: 03 Aug 2016₹2.00
Ex-Date: 10 Sept 2015₹2.00
Ex-Date: 10 Jul 2014₹2.00
Ex-Date: 18 Jul 2013₹2.00
Bulk & block deals
Recent large transactions
DateClientTypeQtyPrice
25 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE3,02,621₹397.90
25 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE3,02,621₹397.90
25 Oct 2022ISHARES INDIA SC MAURITIUS COMPANYSALE39,265₹397.90
25 Oct 2022ISHARES MSCI INDIA SMALL-CAP ETFPURCHASE39,265₹397.90
17 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE3,02,331₹390.85
17 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE3,02,331₹390.85
17 Oct 2022ISHARES INDIA SC MAURITIUS COMPANYSALE39,226₹390.85
17 Oct 2022ISHARES MSCI INDIA SMALL-CAP ETFPURCHASE39,226₹390.85
11 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE2,94,302₹393.10
11 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE2,94,302₹393.10
11 Oct 2022ISHARES INDIA SC MAURITIUS COMPANYSALE38,184₹393.10
11 Oct 2022ISHARES MSCI INDIA SMALL-CAP ETFPURCHASE38,184₹393.10

Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.